Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial

Figure 3

Effect of DC vaccines on tumor progression and CTL induction in patient 2. A; Maintenance of progression-free status for as long as 34 months by DC vaccines after surgical resection as revealed by MRI. B; Remarkable CTL activity after 8 DC vaccines as revealed by ELISPOT assay. The spot number per well of peptide-stimulated CTLs was compared to that of a negative well without peptide using Student’s paired two-tailed t-test. Statistically significant compared to no peptide, *; P < 0.05, **; P < 0.01. None; no peptide.

Back to article page